Page 95 - ஸ்கிரிப்ட்கள் ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Science s COVID-19 reporting is supported by the Heising-Simons Foundation ILLUSTRATION: STEPHAN SCHMITZ/FOLIO ART In March 2020, as the scope of the COVID-19 pandemic was coming into view, Jen Nwankwo and colleagues turned a pair of artificial intelligence (AI) tools against SARS-CoV-2. One newly developed AI program, called SUEDE, digitally screens all known druglike compounds for likely activity against biomolecules thought to be involved in disease. The other, BAGEL, predicts how to build inhibitors to known targets. The two programs searched for compounds able to block human enzymes that play essential roles in enabling the virus to infect our cells. While SUEDE sifted through 14 billion compounds in just hours and spit out a hit, BAGEL made equally fast work of designing a lead. Nwankwo, CEO of a Massachusetts biotech startup called 1910 Genetics, asked a chemical company partner to synthesize the compounds. A week or so later, her team received the orders, added each compou

University of massachusetts medical schoolUnited statesUnited kingdomFrancis collinsDavid bakerMatthew disneyCelia schifferRidgeback biotherapeuticsJen nwankwoSandra wellerEmmeline blanchardMark denisonAnnaliesa andersonEvrys bioDaniel vittMarla weetall